search
Back to results

ROTEM-guided Transfusion Protocol in Attempt to Reduce Blood Transfusions in Major Oncological Surgery (ROTEM-SUR)

Primary Purpose

Blood Loss, Surgical, Blood Loss Requiring Transfusion, Coagulation Defect; Acquired

Status
Withdrawn
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Rotational thromboelastometry
Conventional treatment
Sponsored by
Tampere University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Blood Loss, Surgical focused on measuring ROTEM, thromboelastometry, blood transfusion, cancer, surgery, abdominal, oncological

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age over 18, radical cystectomy, total or partial nephrectomy for malignant disease or pancreaticoduodenectomy planned and estimated intraoperative hemorrhage over 1500ml, written and informed consent

Exclusion Criteria:

  • Known hemophilia or von Willebrandt's disease (treatment planned beforehand in collaboration with haematologist), unacceptance of allogeneic blood products (jehovah's witnesses).

Sites / Locations

  • Tampere University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ROTEM-arm

Control-arm

Arm Description

Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.

Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).

Outcomes

Primary Outcome Measures

Number of transfused red blood cell (RBC) units
Red blood cell units transfused per patient during operation or up to 24 hours after beginning of surgery

Secondary Outcome Measures

Intensive care admissions
Number of patients admitted to intensive care or high dependency, if this is considered associating with the surgery
Length of hospital stay
Number of days patient is in hospital immediately after surgery
Transfusion-related side effects
Any side-effect considered or suspected originating from blood product transfusion
Thromboembolic events
Clinically diagnosed deep vein thrombosis, pulmonary embolism, stroke or other thromboembolic event

Full Information

First Posted
June 18, 2019
Last Updated
December 14, 2020
Sponsor
Tampere University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03993977
Brief Title
ROTEM-guided Transfusion Protocol in Attempt to Reduce Blood Transfusions in Major Oncological Surgery
Acronym
ROTEM-SUR
Official Title
ROTEM-guided Transfusion Protocol Versus Standard Care in Attempt to Reduce Blood Transfusions in Potentially Curative Major Abdominal and Urological Oncological Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Due to changes in the surgical technique, no potential subjects anymore
Study Start Date
May 1, 2020 (Anticipated)
Primary Completion Date
October 13, 2020 (Actual)
Study Completion Date
October 13, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tampere University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Need for perioperative blood transfusion is still high in certain types of oncological abdominal surgery. Allogeneic blood transfusion may be detrimental in cancer patients undergoing a potentially curative resection of malignant tumor, although the detailed mechanism of this effect is still under debate. We plan to evaluate whether a new, rotational thromboelastography-guided algorithm (ROTEM) to guide hemostatic resuscitation intra-operatively decreases the use of allogeneic blood products, the total amount of bleeding, transfusion related side effects, thromboembolic complications and costs. Its effect on each patient's post-operative hemostatic profile is also measured. 60 patients having a potentially curative pancreaticoduodenectomy (or resection of cauda of pancreas), total removal or partial resection of kidney and open radical cystectomy are recruited when an active blood loss of more than 1500 ml is estimated and/or measured and are randomized into two groups: one will be treated conventionally, ie. using massive transfusion protocol (MTP) if necessary, clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Loss, Surgical, Blood Loss Requiring Transfusion, Coagulation Defect; Acquired
Keywords
ROTEM, thromboelastometry, blood transfusion, cancer, surgery, abdominal, oncological

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
60 patients having a potentially curative abdomino-oncological surgery and reaching an active blood loss of more than 1500 ml are randomized into two groups. One will be treated conventionally, ie. using MTP if necessary, clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm. Randomization (ratio 1:1 in blocks of 10) between the two groups will be done beforehand. Each paper containing the treatment protocol in question will be put into a closed envelope. The envelopes are numbered from 1 to 60 and are placed in a box in the operative department.
Masking
ParticipantOutcomes Assessor
Masking Description
Participants do not know which group he/she is randomized into. They are under general anaesthesia, thus not knowing which protocol is used. When assessing outcomes, two groups are labeled only by number: the assessor does not know which arm is number 1 or 2 until whole data is analyzed.
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ROTEM-arm
Arm Type
Experimental
Arm Description
Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
Arm Title
Control-arm
Arm Type
Active Comparator
Arm Description
Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
Intervention Type
Diagnostic Test
Intervention Name(s)
Rotational thromboelastometry
Other Intervention Name(s)
ROTEM
Intervention Description
ROTEM-guided protocol of hemostatic resuscitation
Intervention Type
Other
Intervention Name(s)
Conventional treatment
Intervention Description
Clinical judgement and conventional coagulation tests
Primary Outcome Measure Information:
Title
Number of transfused red blood cell (RBC) units
Description
Red blood cell units transfused per patient during operation or up to 24 hours after beginning of surgery
Time Frame
24 hours after beginning of surgery
Secondary Outcome Measure Information:
Title
Intensive care admissions
Description
Number of patients admitted to intensive care or high dependency, if this is considered associating with the surgery
Time Frame
30 days after surgery
Title
Length of hospital stay
Description
Number of days patient is in hospital immediately after surgery
Time Frame
30 days after surgery
Title
Transfusion-related side effects
Description
Any side-effect considered or suspected originating from blood product transfusion
Time Frame
30 days after surgery
Title
Thromboembolic events
Description
Clinically diagnosed deep vein thrombosis, pulmonary embolism, stroke or other thromboembolic event
Time Frame
30 days after surgery
Other Pre-specified Outcome Measures:
Title
Signs of altered coagulation
Description
Possible signs hypercoagulopathy in thromboelastometry: EXTEM value of more than 72 mm
Time Frame
12-24 hours after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age over 18, radical cystectomy, total or partial nephrectomy for malignant disease or pancreaticoduodenectomy planned and estimated intraoperative hemorrhage over 1500ml, written and informed consent Exclusion Criteria: Known hemophilia or von Willebrandt's disease (treatment planned beforehand in collaboration with haematologist), unacceptance of allogeneic blood products (jehovah's witnesses).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Kuitunen, MD, PhD
Organizational Affiliation
Deputy chief physician
Official's Role
Study Director
Facility Information:
Facility Name
Tampere University Hospital
City
Tampere
ZIP/Postal Code
33560
Country
Finland

12. IPD Sharing Statement

Learn more about this trial

ROTEM-guided Transfusion Protocol in Attempt to Reduce Blood Transfusions in Major Oncological Surgery

We'll reach out to this number within 24 hrs